NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.850
-0.040 (-1.38%)
At close: Oct 9, 2026, 4:00 PM EDT
2.850
0.00 (0.01%)
After-hours: Oct 9, 2026, 7:30 PM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, NRx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $38.5. The average 1-year stock price forecast is 1,250.88% higher than the current stock price, while the lowest is $10 (+250.88%) and the highest is $50 (+1,654.39%).
Price Target: $38.5 (+1,250.88%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant | Ascendiant | Buy Maintains $49 → $50 | Buy | Maintains | $49 → $50 | +1,654.39% | Sep 30, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $45 | Buy | Reiterates | $45 | +1,478.95% | Sep 22, 2026 |
| BTIG | BTIG | Buy Maintains $10 | Buy | Maintains | $10 | +250.88% | Sep 15, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates $49 | Buy | Initiates | $49 | +1,619.30% | May 13, 2026 |
| D. Boral Capital | D. Boral Capital | Buy Maintains $34 | Buy | Maintains | $34 | +1,092.98% | Apr 20, 2026 |
Financial Forecast
Revenue This Year
5.61M
from 1.23M
Increased by 357.94%
Revenue Next Year
90.17M
from 5.61M
Increased by 1,507.30%
EPS This Year
-0.80
from -1.34
EPS Next Year
-0.35
from -0.80
EPS and Forward PE are based on non-GAAP adjusted numbers.